Private Capital Advisors Inc. Sells 71,798 Shares of Immunome, Inc. $IMNM

Private Capital Advisors Inc. cut its holdings in Immunome, Inc. (NASDAQ:IMNM) by 37.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 118,046 shares of the company’s stock after selling 71,798 shares during the period. Private Capital Advisors Inc.’s holdings in Immunome were worth $1,382,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of IMNM. Vanguard Group Inc. boosted its position in Immunome by 8.1% in the third quarter. Vanguard Group Inc. now owns 4,893,626 shares of the company’s stock worth $57,304,000 after purchasing an additional 368,674 shares during the last quarter. Geode Capital Management LLC grew its position in Immunome by 6.7% during the second quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock valued at $17,305,000 after buying an additional 117,523 shares during the period. Principal Financial Group Inc. increased its holdings in Immunome by 222.3% during the third quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock worth $12,939,000 after buying an additional 762,147 shares during the last quarter. Candriam S.C.A. raised its position in Immunome by 170.2% in the third quarter. Candriam S.C.A. now owns 859,527 shares of the company’s stock worth $10,065,000 after acquiring an additional 541,441 shares during the period. Finally, TD Asset Management Inc boosted its stake in Immunome by 15.8% in the third quarter. TD Asset Management Inc now owns 701,280 shares of the company’s stock valued at $8,212,000 after acquiring an additional 95,750 shares during the last quarter. 44.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on IMNM. Evercore raised their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Truist Financial assumed coverage on Immunome in a report on Monday, December 1st. They set a “buy” rating and a $36.00 price objective for the company. Lake Street Capital boosted their target price on Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Stephens upped their price target on Immunome from $25.00 to $33.00 and gave the company an “overweight” rating in a research report on Monday, November 17th. Finally, Guggenheim lifted their price objective on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, December 16th. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.75.

Insiders Place Their Bets

In other Immunome news, Director Isaac Barchas sold 383,200 shares of Immunome stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the completion of the transaction, the director owned 2,031,181 shares of the company’s stock, valued at $44,157,874.94. The trade was a 15.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the completion of the transaction, the insider owned 43,300 shares of the company’s stock, valued at approximately $887,217. This trade represents a 30.03% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 68,518 shares of company stock worth $1,453,958 in the last quarter. 7.69% of the stock is owned by company insiders.

Immunome Price Performance

Immunome stock opened at $22.14 on Thursday. The firm has a market capitalization of $2.44 billion, a P/E ratio of -7.51 and a beta of 2.32. Immunome, Inc. has a one year low of $5.15 and a one year high of $27.65. The business has a fifty day moving average price of $22.73 and a 200-day moving average price of $17.15.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.